<DOC>
	<DOCNO>NCT00186407</DOCNO>
	<brief_summary>To evaluate role high dose therapy autologous hematopoietic cell transplant amyloidosis .</brief_summary>
	<brief_title>Autologous Stem Cell Rescue Primary Amyloidosis</brief_title>
	<detailed_description>To learn use high dose chemotherapy follow transplantation use peripheral blood stem cell .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>1 . Primary amyloidosis 2 . Age &lt; 75 year . 3 . Patients must pathology review diagnosis confirm Stanford University Medical Center . 4 . Patients undergone bone marrow transplantation previously eligible . 5 . Patients must Karnofsky performance status great 70 % . 6 . Patients must serum creatinine less 2 mg/dl creatinine clearance great 30 ml/min , bilirubin le 2 mg/dl , transaminases less two time normal , leave ventricular ejection fraction &gt; 45 % echocardiography , cardiac index &gt; 1.8 liters/min/m^2 pulmonary function test demonstrate FEV1 DLCO &gt; 60 % . 7 . Patients must HIV negative . 8 . Pregnant lactate woman eligible participate . 9 . Patients must provide sign informed consent . 10 . Patients multiple myeloma amyloid eligible . 1. prior blood marrow transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>